Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells
- PMID: 19787243
- DOI: 10.3892/or_00000558
Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells
Abstract
In the course of gastric cancer development, gene silencing by DNA hypermethylation is an important mechanism. While DNA methylation often co-exists with histone modifications to regulate gene expression, the function of histone modifications in gene silencing in gastric cancer has not been evaluated in detail. p16, a well-known tumor suppressor gene, is frequently silenced in DNA hypermethylation manner in gastric cancer. Accordingly, we chose p16 to clarify whether there is a correlation among histone H3 lysine 9 (H3-K9) di-methylation, H3-K9 acetylation, DNA methylation and p16 expression in human gastric cancer. Three gastric cancer cells, MKN-45, SGC-7901 and BGC-823, were treated with 5-aza-2'-deoxycytidine (5-Aza-dC) and/or trichostatin A (TSA). We investigated p16 promoter DNA methylation status, p16 mRNA levels, regional and global levels of di-methyl-H3-K9 and acetyl-H3-K9 in four groups: i) 5-Aza-dC, ii) TSA, iii) the combination of 5-Aza-dC and TSA and iv) control group with no treatments. p16 silencing is characterized by DNA hypermethylation, H3-K9 hypoacetylation and H3-K9 hypermethylation at the promoter region. Treatment with TSA, increased H3-K9 acetylation at the hypermethylated promoter, but did not affect H3-K9 di-methylation or p16 expression. By contrast, treatment with 5-Aza-dC, reduced H3-K9 di-methylation, increased H3-K9 acetylation at the hypermethylated promoter and reactivated the expression of p16. Combined treatment restored the expression of p16 synergistically. In addition, 5-Aza-dC and the combined treatment did not result in global alteration of H3-K9 di-methylation. These results suggest that H3-K9 di-methylation, H3-K9 acetylation and DNA methylation work in combination to silence p16 in gastric cancer. The decreased H3-K9 di-methylation correlates with DNA demethylation and reactivation of p16. H3-K9 di-methylation as well as DNA methylation related to p16 silencing is limited to the promoter region. In addition to its effect on DNA methylation, 5-Aza-dC can act at histone modification levels to reactivate p16 expression in region-specific and DNA methylation-dependent manner.
Similar articles
-
Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.World J Gastroenterol. 2007 Dec 14;13(46):6166-71. doi: 10.3748/wjg.v13.i46.6166. World J Gastroenterol. 2007. PMID: 18069755 Free PMC article.
-
Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.BMC Cancer. 2010 Jul 12;10:366. doi: 10.1186/1471-2407-10-366. BMC Cancer. 2010. PMID: 20618997 Free PMC article.
-
DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells.Mol Med Rep. 2011 Nov-Dec;4(6):1273-8. doi: 10.3892/mmr.2011.557. Epub 2011 Aug 16. Mol Med Rep. 2011. PMID: 21850374
-
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.Curr Med Chem Anticancer Agents. 2003 May;3(3):187-99. doi: 10.2174/1568011033482440. Curr Med Chem Anticancer Agents. 2003. PMID: 12769777 Review.
-
Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.Biochimie. 2012 Nov;94(11):2297-307. doi: 10.1016/j.biochi.2012.05.029. Epub 2012 Jun 9. Biochimie. 2012. PMID: 22687603 Free PMC article. Review.
Cited by
-
Modulating epigenetic modifications for cancer therapy (Review).Oncol Rep. 2023 Mar;49(3):59. doi: 10.3892/or.2023.8496. Epub 2023 Feb 17. Oncol Rep. 2023. PMID: 36799181 Free PMC article. Review.
-
Increased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.Front Oncol. 2022 Jul 6;12:912101. doi: 10.3389/fonc.2022.912101. eCollection 2022. Front Oncol. 2022. PMID: 35875094 Free PMC article.
-
ASF1B Promotes Oncogenesis in Lung Adenocarcinoma and Other Cancer Types.Front Oncol. 2021 Sep 9;11:731547. doi: 10.3389/fonc.2021.731547. eCollection 2021. Front Oncol. 2021. PMID: 34568067 Free PMC article.
-
PSD3 is an oncogene that promotes proliferation, migration, invasion, and G1/S transition while inhibits apoptotic in papillary thyroid cancer.J Cancer. 2021 Jul 13;12(18):5413-5422. doi: 10.7150/jca.60885. eCollection 2021. J Cancer. 2021. PMID: 34405004 Free PMC article.
-
ASF1B promotes cervical cancer progression through stabilization of CDK9.Cell Death Dis. 2020 Aug 26;11(8):705. doi: 10.1038/s41419-020-02872-5. Cell Death Dis. 2020. PMID: 32848135 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials